0
October 9, 1991, Vol 266, No. 14 >
ARTICLE | October 9, 1991

Insulin-like Growth Factor and Apolipoprotein B FREE

Richard E. Ostlund, Jr, MD; Myrlene A. Staten, MD; Wendy M. Kohrt, PhD; Kathleen A. Obert, RD; William H. Daughaday, MD
JAMA. 1991;266(14):1937-1938. doi:10.1001/jama.1991.03470140049019
Text Size: A A A
Published online
Article
References

To the Editor.  —Apolipoprotein B (apo B) is the principal protein component of the atherogenic lipoproteins low-density (LDL) and very-low-density (VLDL). The factors that regulate plasma apo B levels are of particular interest since in some data apo B is more closely related to coronary heart disease than LDL or VLDL cholesterol.1 We wondered whether insulin-like growth factor I (IGF-I) might be such a factor since the infusion of recombinant IGF-I recently was reported to lower plasma cholesterol levels.2-4 Indeed, previous work had shown that IGF-I deficiency states were accompanied by hypercholesterolemia.5-7 Our hypothesis was that apo B—containing lipoproteins were inversely related to circulating IGF-I in normal subjects.Insulin-like growth factor I,8 insulin-like growth factor II (IGF-II),9 and apo B10 were measured in serum frozen at —70° obtained from 148 well-characterized, healthy men and women between the ages of 60 and 70 years for

REFERENCES

1 +
Sniderman A, Shapiro S, Marpole D, Skinner B, Teng B, Kwiterovich PO Jr.  Association of coronary atherosclerosis with hyperapobetalipoproteinemia (increased protein but normal cholesterol levels in human plasma low-density (B) lipoproteins). Proc Natl Acad Sci USA . 1980;;77:604-608.
2 +
Lieberman SA, Chen SA, Albu BV, et al. Effects of multiple injections of rhIGF-I on free IGF-I disposition and glycemic response in humans. Second International Symposium on Insulin-like Growth Factors/Somatomedins; 1991; Abstract D 3.
3 +
Guler HP, Zapf J, Schmid C, Froesch ER.  Effects of rhIGF-I in man: possible therapeutic usefulness in states characterized by relative insulin resistance and in kidney disease.  In: Sara VR, Hall K, Loew H, eds. Growth Factors: From Genes to Clinical Application . New York, NY: Raven Press; 1990;:217-225.
4 +
Laron Z, Klinger B, Erster B. Biochemical and hormonal effects of 7-day administration of rhIGF-I to Laron-type dwarfism (LTD) patients. In: Program of the Endocrine Society Annual Meeting; 1990. Abstract 204.
5 +
Salomon F, Cuneo RC, Hesp R, Sonksen PH.  The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med . 1989;;321:1797-1803.
6 +
Merimee TJ.  Familial combined hyperlipoproteinemia: evidence for a role of growth hormone deficiency in effecting its manifestation. J Clin Invest . 1980;;65:829-835.
7 +
Hoogerbrugge-v.d.Linden N, Jansen H, Hülsmann WC, Birkenhäger JC.  Relationship between insulin-like growth factor-I and low-density lipoprotein cholesterol levels in primary hypothyroidism in women. J Endocrinol . 1989;;123: 341-345.
8 +
Furlanetto RW, Underwood LE, Van Wyk JJ, D'Ercole AJ.  Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay. J Clin Invest . 1977;;60:648-657.
9 +
Daughaday WH, Kapadia M.  Significance of abnormal serum binding of insulin-like growth factor II in the development of hypoglycemia in patients with non-islet-cell tumors. Proc Natl Acad Sci USA . 1989;;86:6778-6782.
10 +
Ordovas JM, Peterson JP, Santaniello P, Cohn JS, Wilson PWF, Schaefer EJ.  Enzyme-linked immunosorbent assay for human plasma apolipoprotein B. J Lipid Res . 1987;;28:1216-1224.
11 +
Ostlund RE Jr, Staten M, Kohrt WM, Schultz J, Malley M.  The ratio of waist-to-hip circumference, plasma insulin level, and glucose intolerance as independent predictors of the HDL2 cholesterol level in older adults. N Engl J Med . 1990;;322:229-234.
12 +
Chait A, Ross R, Albers JJ, Bierman EL.  Plateletderived growth factor stimulates activity of low-density lipoprotein receptors. Proc Natl Acad Sci USA . 1980;;77:4084-4088.
13 +
Veldhuis JD, Nestler JE, Strauss JF III.  The insulin-like growth factor, somatomedin-C, modulates low-density lipoprotein metabolism by swine granulosa cells. Endocrinology . 1987;;121:340-346.
14 +
NimerSD, Champlin RE, Golde DW.  Serum cholesterol-lowering activity of granulocyte-macrophage colony-stimulating factor. JAMA . 1988;;260:3297-3300.
15 +
Vega GL, Grundy SM.  Does measurement of apolipoprotein B have a place in cholesterol management? Arteriosclerosis . 1990;;10:668-671.

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

1 +
Sniderman A, Shapiro S, Marpole D, Skinner B, Teng B, Kwiterovich PO Jr.  Association of coronary atherosclerosis with hyperapobetalipoproteinemia (increased protein but normal cholesterol levels in human plasma low-density (B) lipoproteins). Proc Natl Acad Sci USA . 1980;;77:604-608.
2 +
Lieberman SA, Chen SA, Albu BV, et al. Effects of multiple injections of rhIGF-I on free IGF-I disposition and glycemic response in humans. Second International Symposium on Insulin-like Growth Factors/Somatomedins; 1991; Abstract D 3.
3 +
Guler HP, Zapf J, Schmid C, Froesch ER.  Effects of rhIGF-I in man: possible therapeutic usefulness in states characterized by relative insulin resistance and in kidney disease.  In: Sara VR, Hall K, Loew H, eds. Growth Factors: From Genes to Clinical Application . New York, NY: Raven Press; 1990;:217-225.
4 +
Laron Z, Klinger B, Erster B. Biochemical and hormonal effects of 7-day administration of rhIGF-I to Laron-type dwarfism (LTD) patients. In: Program of the Endocrine Society Annual Meeting; 1990. Abstract 204.
5 +
Salomon F, Cuneo RC, Hesp R, Sonksen PH.  The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med . 1989;;321:1797-1803.
6 +
Merimee TJ.  Familial combined hyperlipoproteinemia: evidence for a role of growth hormone deficiency in effecting its manifestation. J Clin Invest . 1980;;65:829-835.
7 +
Hoogerbrugge-v.d.Linden N, Jansen H, Hülsmann WC, Birkenhäger JC.  Relationship between insulin-like growth factor-I and low-density lipoprotein cholesterol levels in primary hypothyroidism in women. J Endocrinol . 1989;;123: 341-345.
8 +
Furlanetto RW, Underwood LE, Van Wyk JJ, D'Ercole AJ.  Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay. J Clin Invest . 1977;;60:648-657.
9 +
Daughaday WH, Kapadia M.  Significance of abnormal serum binding of insulin-like growth factor II in the development of hypoglycemia in patients with non-islet-cell tumors. Proc Natl Acad Sci USA . 1989;;86:6778-6782.
10 +
Ordovas JM, Peterson JP, Santaniello P, Cohn JS, Wilson PWF, Schaefer EJ.  Enzyme-linked immunosorbent assay for human plasma apolipoprotein B. J Lipid Res . 1987;;28:1216-1224.
11 +
Ostlund RE Jr, Staten M, Kohrt WM, Schultz J, Malley M.  The ratio of waist-to-hip circumference, plasma insulin level, and glucose intolerance as independent predictors of the HDL2 cholesterol level in older adults. N Engl J Med . 1990;;322:229-234.
12 +
Chait A, Ross R, Albers JJ, Bierman EL.  Plateletderived growth factor stimulates activity of low-density lipoprotein receptors. Proc Natl Acad Sci USA . 1980;;77:4084-4088.
13 +
Veldhuis JD, Nestler JE, Strauss JF III.  The insulin-like growth factor, somatomedin-C, modulates low-density lipoprotein metabolism by swine granulosa cells. Endocrinology . 1987;;121:340-346.
14 +
NimerSD, Champlin RE, Golde DW.  Serum cholesterol-lowering activity of granulocyte-macrophage colony-stimulating factor. JAMA . 1988;;260:3297-3300.
15 +
Vega GL, Grundy SM.  Does measurement of apolipoprotein B have a place in cholesterol management? Arteriosclerosis . 1990;;10:668-671.

Letters

Submit a Letter
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general journals
BMJ 2010;341:c5893-c1494.
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

© 2012 American Medical Association. All Rights Reserved.
Powered bySilverchair Information Systems